SBG reports research funding from AstraZeneca, Boehringer Ingelheim, and Mirati, and consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Blueprint Medicine, Sanofi Genzyme, Daiichi-Sankyo, Regeneron, Takeda, and Janssen, all outside the scope of this work; and consulting fees from Amgen on the use of sotorasib for KRAS-mutant lung cancer. RSH reports Board of Directors participation for Immunocore and Shanghai Junshi Biosciences, research support from AstraZeneca, Genentech, and Merck; consulting fees from AstraZeneca, Bolt Biotherapeutics, Bristol-Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure Biotechnology, Eli Lilly and Company, EMD Serono, Genentech, Giliad, HiberCell, I-Mab Biopharma, Immune-Onc Therapeutics, Immunocore, Janssen, Johnson and Johnson, Loxo Oncology, Merck and Company, NextCure, Novartis, Ocean Biomedical, Oncocyte Corp, Oncternal Therapeutics, Pfizer, Regeneron, Revelar Biotherapeutics, Ribbon Therapeutics, Roche, Sanofi, Xencor, and stock or stock options from Immunocore a company that does work in T cell biology, all outside the scope of this work; consulting fees from Mirati Therapeutics on the use of adagrasib for KRAS-mutant lung cancer, and leadership on the LungMAP Amgen-supported clinical trial with sotorasib in KRAS-mutant lung cancer.